Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patient

Journal of Pharmacological Sciences

Volumn 125, Issue 2, 2014, Pages 150-156

  Luo, Shun Bin ^a   Li, Chuan Bao ^b   Dai, Da Peng ^c   Wang, Shuang Hu ^a,d   Wang, Zhen He ^a   Geng, Pei Wu ^a   Cai, Jie ^a   Jiang, Zhe Li ^a   Pu, Cheng Wei ^e   Shang, Ke ^e   Yuan, Xin Min ^f   Cao, Ya Po ^g   Hu, Guo Xin ^a   Cai, Jian Ping ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c BEIJING HOSPITAL   (China)

^d LISHUI PEOPLE S HOSPITAL   (China)

^e PEKING UNIVERSITY FIRST HOSPITAL   (China)

^f FUWAI HOSPITAL   (China)

^g FIRST HOSPITAL OF TSINGHUA UNIVERSITY   (China)

Author keywords

Allelic variant; CYP2C9; Functional analysis in vitro; Insect cell microsome

Indexed keywords

ALANINE; CYSTEINE; CYTOCHROME P450 2C9; DICLOFENAC; LOSARTAN; TOLBUTAMIDE; WARFARIN; ANTICOAGULANT AGENT;

AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; CODON; CYP2C9 GENE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENETIC CODE; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; METABOLIC RATE; MICROSOME; MUTATIONAL ANALYSIS; POINT MUTATION; PROTEIN EXPRESSION; WILD TYPE; CHEMISTRY; DRUG RESISTANCE; ENZYMOLOGY; GENETIC ASSOCIATION STUDY; GENETIC VARIATION; GENETICS; INBORN ERROR OF METABOLISM; METABOLISM;

AGED; ALLELES; AMINO ACID SUBSTITUTION; ANTICOAGULANTS; CYTOCHROME P-450 CYP2C9; DRUG RESISTANCE; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; HUMANS; METABOLISM, INBORN ERRORS; MICROSOMES; POINT MUTATION; WARFARIN;

EID: 84903939581     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13189FP     Document Type: Article

References (25)

1. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, et al. Interindividual variability in sensitivity to warfarin - Nature or nurture? Clin Pharmacol Ther. 2001;70: 159-164.
2. Suzuki Y, Nagai N, Umemura K. Novel situations of endothelial injury in stroke - mechanisms of stroke and strategy of drug development: intracranial bleeding associated with the treatment of ischemic stroke: thrombolytic treatment of ischemia-affected endothelial cells with tissue-type plasminogen activator. J Pharmacol Sci. 2011;116:25-29.
3. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther. 2004; 75:204-212. (Pubitemid 38314870)
4. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A, et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 2005;5:193-202. (Pubitemid 40852221)
5. Tatarunas V, Lesauskaite V, Veikutiene A, Grybauskas P, Jakuska P, Benetis R. The combined effects of clinical factors and CYP2C9 and VKORC1 gene polymorphisms on initiating warfarin treatment in patients after cardiac valve surgery. J Heart Valve Dis. 2012;21:628-635.
6. Lu Y, Yang J, Zhang H, Yang J. Prediction of warfarin maintenance dose in han chinese patients using a mechanistic model based on genetic and non-genetic factors. Clin Pharmacokinet. 2013;52:567-581.
7. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717-719. (Pubitemid 29103806)
8. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009;113:784-792.
9. Ucar M, Alagozlu H, Sahin S, Ozdemir O. The relationship between CYP2C9 gene polymorphisms and upper gastrointestinal bleeding in patients who used warfarin. Med Glas (Zenica). 2013;10:50-54.
10. Jorgensen AL, Fitz Gerald RJ, Oyee J, Pirmohamed M, Williamson PR. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One. 2012;7:e44064.
11. Liang R, Wang C, Zhao H, Huang J, Hu D, Sun Y. Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. Thromb Res. 2012;130:38-44.
12. Daly AK. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. Arch Toxicol. 2013;87:407-420.
13. Dai DP, Xu RA, Hu LM, Wang SH, Geng PW, Yang JF, et al. CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database. Pharmacogenomics J. 2014;14:85-92.
14. Dai DP, Wang SH, Wang YH, Geng PW, Hu LM, Hu GX, et al. In vitro functional characterization of 37 CYP2C9 allelic isoforms detected in the Chinese Han population. Acta Pharmacol Sin. 2013;34:1449-1456.
15. Wang YH, Pan PP, Dai DP, Wang SH, Geng PW, Cai JP, et al. Effect of 36 CYP2C9 variants found in the Chinese population on losartan metabolism in vitro. Xenobiotica. 2014;44:270-275.
16. Niinuma Y, Saito T, Takahashi M, Tsukada C, Ito M, Hirasawa N, et al. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J. 2014;14:107-114.
17. Hiratsuka M. In vitro assessment of the allelic variants of cytochrome P450. Drug Metab Pharmacokinet. 2012;27:68-84.
18. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet. 2005;14:1745-1751. (Pubitemid 41430097)
19. Burmester JK, Berg RL, Glurich I, Yale SH, Schmelzer JR, Caldwell MD. Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses. Clin Med Res. 2011;9:119-124.
20. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, Jhoti H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature. 2003;424:464-468. (Pubitemid 36917499)
21. Bordoli L, Schwede T. Automated protein structure modeling with SWISS-MODEL Workspace and the Protein Model Portal. Methods Mol Biol. 2012;857:107-136.
22. Lam MP, Cheung BM. The pharmacogenetics of the response to warfarin in Chinese. Br J Clin Pharmacol. 2012;73:340-347.
23. Zhang W, Zhang WJ, Zhu J, Kong FC, Li YY, Wang HY, et al. Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism. Pharmacogenomics. 2012;13:309-321.
24. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004;14:527-537. (Pubitemid 39106854)
25. Tai G, Farin F, Rieder MJ, Dreisbach AW, Veenstra DL, Verlinde CL, et al. In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics. 2005;15:475-481. (Pubitemid 41017596)